XML 100 R86.htm IDEA: XBRL DOCUMENT
v3.23.2

Other Operating Income And Expenses - Schedule of Other Operating Expenses (Details) - EUR (€) € in Millions | 6 Months Ended | 12 Months Ended
--- | --- | ---
Jun. 30, 2023 | Jun. 30, 2022 | Dec. 31, 2022
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |
Other operating expenses | € (1,422) | € (1,204) | € (2,531)
Other operating income | 617 | 416 | 1,969
Other operating income/(expenses), net related to Regeneron | (1,321) | (1,068) | (1,231)
Other related parties | Other operating income (expense) |  |  |
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |
Other operating income | 160 | 153 |
Monoclonal Antibodies Alliance |  |  |
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |
Other operating expenses | (1,418) | (1,098) | (2,367)
Monoclonal Antibodies Alliance | Income & expense related to profit/loss sharing under the Monoclonal Antibody Alliance |  |  |
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |
Other operating expenses | (1,449) | (979) | (2,325)
Monoclonal Antibodies Alliance | Additional share of profit paid by Regeneron towards development costs |  |  |
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |
Other operating income | 291 | 97 | 434
Monoclonal Antibodies Alliance | Reimbursement to Regeneron of selling expenses incurred |  |  |
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |
Other operating expenses | (260) | (216) | (476)
Immuno-Oncology Alliance |  |  |
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |
Other operating income | 0 | 36 | 16
Other (mainly Zaltrap® and Libtayo®) |  |  |
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |
Other operating income and expenses | 97 | (6) | 1,120
Regeneron | Other operating income (expense) |  |  |
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |
Other operating income | 102 | 133 | € 1,147
Regeneron | Other related parties | Reimbursement to Regeneron of selling expenses incurred |  |  |
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |
Other operating expenses | € (1,423) | € (1,201) |

X
- Definition The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2022-03-24 -Paragraph 112 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_112_c&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_MiscellaneousOtherOperatingExpense
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of miscellaneous other operating income. [Refer: Other operating income (expense)] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2022-03-24 -Paragraph 112 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_112_c&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_MiscellaneousOtherOperatingIncome
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of operating income (expense) that the entity does not separately disclose in the same statement or note. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2022-03-24 -Paragraph 85 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_85&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_OtherOperatingIncomeExpense
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Disclosure of other operating income (expenses). + References No definition available. + Details
Name: | sny_DisclosureOfOtherOperatingIncomeExpensesLineItems
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Other operating income and expenses. + References No definition available. + Details
Name: | sny_MiscellaneousOtherOperatingIncomeExpenses
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sny_OtherOperatingIncomeExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sny_AntibodiesAllianceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sny_CommercializationRelatedExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sny_ImmunoOncologyAllianceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sny_OthersCounterpartyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_RegeneronMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |